MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Short Interest Up 144.9% in December

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) was the target of a significant increase in short interest in December. As of December 15th, there was short interest totaling 1,685,137 shares, an increase of 144.9% from the November 30th total of 687,986 shares. Currently, 6.7% of the shares of the stock are sold short. Based on an average daily trading volume, of 1,479,960 shares, the days-to-cover ratio is currently 1.1 days. Based on an average daily trading volume, of 1,479,960 shares, the days-to-cover ratio is currently 1.1 days. Currently, 6.7% of the shares of the stock are sold short.

Insider Buying and Selling at MAIA Biotechnology

In related news, Director Ngar Yee Louie acquired 81,699 shares of MAIA Biotechnology stock in a transaction dated Monday, December 22nd. The shares were purchased at an average cost of $1.22 per share, with a total value of $99,672.78. Following the completion of the purchase, the director owned 1,248,888 shares of the company’s stock, valued at $1,523,643.36. This represents a 7.00% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Stan Smith purchased 57,189 shares of the firm’s stock in a transaction on Monday, December 22nd. The stock was bought at an average cost of $1.22 per share, for a total transaction of $69,770.58. Following the completion of the purchase, the director directly owned 1,421,478 shares in the company, valued at approximately $1,734,203.16. This trade represents a 4.19% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 368,352 shares of company stock valued at $427,192 over the last ninety days. Insiders own 32.32% of the company’s stock.

Hedge Funds Weigh In On MAIA Biotechnology

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Centerpoint Advisory Group purchased a new stake in MAIA Biotechnology in the second quarter worth about $28,000. Geode Capital Management LLC grew its stake in shares of MAIA Biotechnology by 3.6% during the 2nd quarter. Geode Capital Management LLC now owns 222,183 shares of the company’s stock valued at $400,000 after acquiring an additional 7,746 shares during the period. Centric Wealth Management grew its stake in shares of MAIA Biotechnology by 740.2% during the 2nd quarter. Centric Wealth Management now owns 573,398 shares of the company’s stock valued at $1,032,000 after acquiring an additional 505,150 shares during the period. Marshall Wace LLP purchased a new stake in MAIA Biotechnology in the 2nd quarter worth approximately $29,000. Finally, Jane Street Group LLC bought a new stake in MAIA Biotechnology during the 2nd quarter worth approximately $52,000. 5.65% of the stock is currently owned by hedge funds and other institutional investors.

MAIA Biotechnology Stock Up 6.1%

Shares of NYSEAMERICAN MAIA traded up $0.09 during trading on Friday, reaching $1.57. The company had a trading volume of 761,956 shares, compared to its average volume of 977,358. The stock has a market cap of $58.14 million and a PE ratio of -2.15. MAIA Biotechnology has a 12-month low of $0.87 and a 12-month high of $2.74. The business’s 50-day moving average is $1.22 and its 200 day moving average is $1.50.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last released its quarterly earnings data on Friday, November 7th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.08). On average, analysts anticipate that MAIA Biotechnology will post -1.3 earnings per share for the current year.

About MAIA Biotechnology

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.